Tharimmune regains compliance with Nasdaq listing rule following equity update

Published 05/09/2025, 16:34
Tharimmune regains compliance with Nasdaq listing rule following equity update

Tharimmune, Inc. (NASDAQ:THAR) announced Friday that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after reporting stockholders’ equity of $6,876,335 as of August 31, 2025. The company disclosed in a press release statement that it received a letter from Nasdaq confirming the matter is now closed.

The update follows Tharimmune’s filing of a Form 8-K with the Securities and Exchange Commission, which provided evidence of the company’s equity position. Nasdaq’s Listing Rule 5550(b)(1) requires companies listed on the exchange to maintain a minimum stockholders’ equity threshold.

Tharimmune is incorporated in Delaware and is listed on the Nasdaq Stock Market under the ticker symbol THAR. The company’s principal executive offices are located in Red Bank, New Jersey.

This information is based on a press release statement contained in a recent SEC filing.

In other recent news, Tharimmune, Inc. has reported that its stockholders’ equity now surpasses the minimum requirement for continued listing on the Nasdaq Capital Market. This development follows the company’s recent direct offerings and a private placement, which collectively raised approximately $7.05 million. Additionally, Tharimmune announced a $5.35 million direct offering of common stock, issuing 1,188,888 shares at $4.50 per share. The offering was conducted under a shelf registration statement that became effective earlier this year.

In other updates, Tharimmune revealed positive results from a pharmacokinetic simulation analysis of its lead asset, TH104, which is being developed as a countermeasure against high-potency opioids. The company also expanded its intellectual property portfolio by securing new patents for its TH-104 technology in several countries, extending protection until at least 2040. Furthermore, Tharimmune has made key leadership changes, appointing Sireesh Appajosyula as CEO and Vincent LoPriore as Executive Chairman. These recent developments reflect Tharimmune’s ongoing efforts to advance its pipeline and strengthen its market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.